Paradigm Biopharmaceuticals Ltd.ASX: PAR

Type D Response Submitted and Received by the US FDA

Apr 19, 2024 at 2:57 AM UTC · Issued by Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Ltd has released a press release.

View Attachment